Benzinga

Benzinga

Benzinga

lundi, août 31

Celularity Inc

CELUNASDAQ
Trade with Public
Trade with Public
$1.52
-0.06-3.8%
Dern. MÀJ: Aug 31, 10:28 AM
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Celularity Analyst Price Targets

Wall Street analyst price targets and consensus rating for Celularity (CELU).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$6Upside to Avg. PT+294.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2025WBB SecuritiesSteve BrozakUpgradeHold→Buy$6
Aug 18, 2025WBB SecuritiesSteve BrozakInitiateSpeculative Buy$6

Analyst Ratings News

PRO
WBB Securities Upgrades Celularity to Buy, Maintains Price Target to $6

WBB Securities analyst Steve Brozak upgrades Celularity (NASDAQ:CELU) from Hold to Buy and maintains the price target from $6 to $6.
Benzinga Newsdesk

PRO
WBB Securities Initiates Coverage On Celularity with Speculative Buy Rating, Announces Price Target of $6

WBB Securities analyst Steve Brozak initiates coverage on Celularity (NASDAQ:CELU) with a Speculative Buy rating and announces Price Target of $6.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023

Benzinga Insights

Amazon To Rally Around 29%? Here Are 10 Other Analyst Forecasts For Monday

Barclays cut the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $140 to $130. Barclays analyst Ross Sandler maintained an Overweight rating. Amazon shares fell 1.2% to $101.06 in pre-market trading.
Lisa Levin

PRO
Morgan Stanley Downgrades Celularity to Underweight, Lowers Price Target to $1

Morgan Stanley analyst Jeffrey Hung downgrades Celularity (NASDAQ:CELU) from Equal-Weight to Underweight and lowers the price target from $5 to $1.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Celularity, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celularity (NASDAQ:CELU) with a Buy and lowers the price target from $15 to $2.5.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved